This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
News

NICE Approves Two New Cancer Treatments

NICE has approved two new cancer treatments.

New guidance published on 13th May 2020 recommends obinutuzumab (Gazyvaro) with bendamustine followed by obinutuzumab maintenance for follicular lymphoma that did not respond or progressed ≤6 months after treatment with rituximab or a rituximab-containing regimen. Up until now the treatment has only been available through the Cancer Drugs Fund (CDF).

The normal list price for the treatment is £3312 per 1000 mg vial. However, a commercial arrangement between NICE and the company makes obinutuzumab with bendamustine available to the NHS at a discount.

Cost-effectiveness analysis after taking account of the discounted price delivered an incremental cost-effectiveness ratio (ICER) of £15,045 per quality-adjusted life year (QALY) gained. These ICERs are within the range normally considered to be a cost-effective use of NHS resources (£20,000 to £30,000 per QALY gained).

Additionally, NICE has recommended lorlatinib (Lorviqua) as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The treatment will be available to adults whose disease has progressed after using alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI), or after treatment using crizotinib and ≥1 other ALK TKI.

Previously, lorlatinib had not been recommended as it was not considered a cost-effective use of NHS resources. However, NICE says that following consultation on draft guidance, the company proposed an alternative price for lorlatinib, which has since been accepted as cost-effective for routine commissioning.

This article first appeared on Univadis from Medscape.

YOU MAY ALSO LIKE